In this issue:
Management of patients with AD receiving dupilumab
Dupilumab for AD in paediatric patients
Dermatologist’s attitudes to dose reduction of biologics for psoriasis
Adalimumab + surgery for moderate-to-severe hidradenitis suppurativa
Nemolizumab for AD and moderate-to-severe pruritus
Conjunctivitis with tralokinumab for moderate-to-severe AD
Tildrakizumab for treatment of moderate-to-severe psoriasis
Three-year outcomes of certolizumab pegol for plaque psoriasis
Perception and experience of biologic therapy in AD
Safety of SARS-CoV-2 vaccines in psoriasis patients receiving biologics
Please login below to download this issue (PDF)